Ng, S. B. et al. Exome sequencing identifies the cause of a Mendelian disorder. Nat. Genet. 42, 30\u201335 (2010).<\/p>\n
CAS<\/a>\u00a0 Zhang, F. & Lupski, J. R. Non-coding genetic variants in human disease. Hum. Mol. Genet. 24, R102\u2013R110 (2015).<\/p>\n CAS<\/a>\u00a0 Zoghbi, H. Y. & Beaudet, A. L. Epigenetics and human disease. Cold Spring Harb. Perspect. Biol. 8, a019497 (2016).<\/p>\n Malik, I., Kelley, C. P., Wang, E. T. & Todd, P. K. Molecular mechanisms underlying nucleotide repeat expansion disorders. Nat. Rev. Mol. Cell Biol. 22, 589\u2013607 (2021).<\/p>\n CAS<\/a>\u00a0 Eggermann, T. et al. Imprinting disorders. Nat. Rev. Dis. Primers 9, 33 (2023).<\/p>\n PubMed<\/a>\u00a0 Tabolacci, E. & Chiurazzi, P. Epigenetics, fragile X syndrome and transcriptional therapy. Am. J. Med. Genet. A 161A, 2797\u20132808 (2013).<\/p>\n PubMed<\/a>\u00a0 Hagerman, R. J. et al. Fragile X syndrome. Nat. Rev. Dis. Primers 3, 17065 (2017).<\/p>\n PubMed<\/a>\u00a0 Coffee, B. et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am. J. Hum. Genet. 85, 503\u2013514 (2009).<\/p>\n CAS<\/a>\u00a0 Richter, J. D. & Zhao, X. The molecular biology of FMRP: new insights into fragile X syndrome. Nat. Rev. Neurosci. 22, 209\u2013222 (2021).<\/p>\n CAS<\/a>\u00a0 Dahlhaus, R. Of men and mice: modeling the fragile X syndrome. Front. Mol. Neurosci. 11, 41 (2018).<\/p>\n PubMed<\/a>\u00a0 Vershkov, D. & Benvenisty, N. Human pluripotent stem cells in modeling human disorders: the case of fragile X syndrome. Regen. Med. 12, 53\u201368 (2017).<\/p>\n CAS<\/a>\u00a0 Kumari, D. et al. Identification of fragile X syndrome-specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs. Hum. Mutat. 35, 1485\u20131494 (2014).<\/p>\n CAS<\/a>\u00a0 Brasa, S. et al. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome. Clin. Epigenetics 8, 15 (2016).<\/p>\n PubMed<\/a>\u00a0 Schwartz, P. H. et al. Neural progenitor cells from an adult patient with fragile X syndrome. BMC Med. Genet. 6, 2 (2005).<\/p>\n PubMed<\/a>\u00a0 Bhattacharyya, A. et al. Normal neurogenesis but abnormal gene expression in human fragile X cortical progenitor cells. Stem Cells Dev. 17, 107\u2013117 (2008).<\/p>\n CAS<\/a>\u00a0 Castr\u00e9n, M. et al. Altered differentiation of neural stem cells in fragile X syndrome. Proc. Natl Acad. Sci. USA 102, 17834\u201317839 (2005).<\/p>\n PubMed<\/a>\u00a0 Obernier, K. & Alvarez-Buylla, A. Neural stem cells: origin, heterogeneity and regulation in the adult mammalian brain. Development 146, dev156059 (2019).<\/p>\n CAS<\/a>\u00a0 Bar, S. & Benvenisty, N. Human pluripotent stem cells: derivation and applications. Nat. Rev. Mol. Cell Biol. https:\/\/doi.org\/10.1038\/S41580-020-00309-7<\/a> (2020).<\/p>\n Bhattacharyya, A. & Zhao, X. Human pluripotent stem cell models of fragile X syndrome. Mol. Cell. Neurosci. 73, 43\u201351 (2015).<\/p>\n PubMed<\/a>\u00a0 Mor-Shaked, H. & Eiges, R. Modeling fragile X syndrome using human pluripotent stem cells. Genes 7, 77 (2016).<\/p>\n PubMed<\/a>\u00a0 Vershkov, D., Ben-Hur, T. & Benvenisty, N. in Fragile X Syndrome: from Genetics to Targeted Treatment (eds Willemsen, R. & Kooy, R. F.) 103\u2013121 (Academic, 2017).<\/p>\n Burton, A. & Torres-Padilla, M. E. Epigenome dynamics in early mammalian embryogenesis. Nat. Rev. Genet. https:\/\/doi.org\/10.1038\/s41576-025-00831-4<\/a> (2025).<\/p>\n Eiges, R. et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1, 568\u2013577 (2007).<\/p>\n CAS<\/a>\u00a0 Urbach, A., Bar-Nur, O., Daley, G. Q. & Benvenisty, N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6, 407\u2013411 (2010).<\/p>\n CAS<\/a>\u00a0 Bar-Nur, O., Russ, H. A., Efrat, S. & Benvenisty, N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 9, 17\u201323 (2011).<\/p>\n CAS<\/a>\u00a0 Hu, B. Y. et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 107, 4335\u20134340 (2010).<\/p>\n CAS<\/a>\u00a0 Halevy, T., Czech, C. & Benvenisty, N. Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Reports 4, 37\u201346 (2015).<\/p>\n CAS<\/a>\u00a0 Kang, Y. et al. A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies. Nat. Neurosci. 24, 1377\u20131391 (2021).<\/p>\n CAS<\/a>\u00a0 Lee, A., Xu, J., Wen, Z. & Jin, P. Across dimensions: developing 2D and 3D human iPSC-based models of fragile X syndrome. Cells 11, 1725 (2022).<\/p>\n CAS<\/a>\u00a0 Gunapala, K. M. et al. Ascorbic acid ameliorates molecular and developmental defects in human-induced pluripotent stem cell and cerebral organoid models of fragile X syndrome. Int. J. Mol. Sci. 25, 12718 (2024).<\/p>\n CAS<\/a>\u00a0 Huang, Y. et al. Research progress, challenges, and breakthroughs of organoids as disease models. Front. Cell Dev. Biol. 9, 740574 (2021).<\/p>\n PubMed<\/a>\u00a0 Shivram, H., Cress, B. F., Knott, G. J. & Doudna, J. A. Controlling and enhancing CRISPR systems. Nat. Chem. Biol. 17, 10\u201319 (2020).<\/p>\n PubMed<\/a>\u00a0 Park, C. Y. et al. Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. Cell Rep. 13, 234\u2013241 (2015).<\/p>\n CAS<\/a>\u00a0 Xie, N. et al. Reactivation of FMR1 by CRISPR\/Cas9-mediated deletion of the expanded CGG-repeat of the fragile X chromosome. PLoS ONE 11, e0165499 (2016).<\/p>\n PubMed<\/a>\u00a0 Fischer, L. A., Khan, S. A. & Theunissen, T. W. Induction of human na\u00efve pluripotency using 5i\/L\/A medium. Methods Mol. Biol. 2416, 13\u201328 (2022).<\/p>\n CAS<\/a>\u00a0 Lee, H. G. et al. Site-specific R-loops induce CGG repeat contraction and fragile X gene reactivation. Cell 186, 2593\u20132609 (2023).<\/p>\n CAS<\/a>\u00a0 Williams, K., Christensen, J. & Helin, K. DNA methylation: TET proteins\u2014guardians of CpG islands? EMBO Rep. 13, 28\u201335 (2012).<\/p>\n CAS<\/a>\u00a0 Groh, M. & Gromak, N. Out of balance: R-loops in human disease. PLoS Genet. 10, e1004630 (2014).<\/p>\n PubMed<\/a>\u00a0 Smeets, H. J. M. et al. Normal phenotype in two brothers with a full FMR1 mutation. Hum. Mol. Genet. 4, 2103\u20132108 (1995).<\/p>\n CAS<\/a>\u00a0 Liu, X. S. et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell 172, 979\u2013992 (2018).<\/p>\n CAS<\/a>\u00a0 Haenfler, J. M. et al. Targeted reactivation of FMR1 transcription in fragile X syndrome embryonic stem cells. Front. Mol. Neurosci. 11, 282 (2018).<\/p>\n PubMed<\/a>\u00a0 Tseng, E., Tang, H. T., AlOlaby, R. R., Hickey, L. & Tassone, F. Altered expression of the FMR1 splicing variants landscape in premutation carriers. Biochim Biophys. Acta Gene Regul. Mech. 1860, 1117\u20131126 (2017).<\/p>\n CAS<\/a>\u00a0 Shah, S. et al. Antisense oligonucleotide rescue of CGG expansion dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. Proc. Natl Acad. Sci. USA 120, e2302534120 (2023).<\/p>\n CAS<\/a>\u00a0 Colak, D. et al. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science 343, 1002\u20131005 (2014).<\/p>\n CAS<\/a>\u00a0 Paluszkiewicz, S. M., Martin, B. S. & Huntsman, M. M. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev. Neurosci. 33, 349\u2013364 (2011).<\/p>\n CAS<\/a>\u00a0 Berry-Kravis, E. et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci. Transl. Med. 8, 321ra325 (2016).<\/p>\n Grabb, M. C. & Potter, W. Z. CNS trial failures: using the fragile X syndrome-mGluR5 drug target to highlight the complexities of translating preclinical discoveries into human trials. J. Clin. Psychopharmacol. 42, 234\u2013237 (2022).<\/p>\n PubMed<\/a>\u00a0 Kurosaki, T. et al. Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay. Nat. Cell Biol. 23, 40\u201348 (2021).<\/p>\n CAS<\/a>\u00a0 Kumari, D. et al. High-throughput screening to identify compounds that increase fragile X mental retardation protein expression in neural stem cells differentiated from fragile X syndrome patient-derived induced pluripotent stem cells. Stem Cells Transl. Med. 4, 800\u2013808 (2015).<\/p>\n CAS<\/a>\u00a0 Vershkov, D. et al. FMR1 reactivating treatments in fragile X iPSC-derived neural progenitors in vitro and in vivo. Cell Rep. 26, 2531\u20132539 (2019).<\/p>\n CAS<\/a>\u00a0 Hunt, J. F. V. et al. High throughput small molecule screen for reactivation of FMR1 in fragile X syndrome human neural cells. Cells 11, 69 (2022).<\/p>\n CAS<\/a>\u00a0 Hagemann, S., Heil, O., Lyko, F. & Brueckner, B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE 6, e17388 (2011).<\/p>\n CAS<\/a>\u00a0 Thota, S., Oganesian, A., Azab, M. & Griffiths, E. A. Role of cedazuridine\/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. Future Oncol. 17, 2077\u20132087 (2021).<\/p>\n CAS<\/a>\u00a0 Vershkov, D., Yilmaz, A., Yanuka, O., Nielsen, A. L. & Benvenisty, N. Genome-wide screening for genes involved in the epigenetic basis of fragile X syndrome. Stem Cell Reports 17, 1048\u20131058 (2022).<\/p>\n CAS<\/a>\u00a0 Mulley, J. C. et al. FRAXE and mental retardation. J. Med. Genet. 32, 162\u2013169 (1995).<\/p>\n CAS<\/a>\u00a0 Gecz, J., Gedeon, A. K., Sutherland, G. R. & Mulley, J. C. Identification of the gene FMR2, associated with FRAXE mental retardation. Nat. Genet. 13, 105\u2013108 (1996).<\/p>\n CAS<\/a>\u00a0 Youings, S. A. et al. FRAXA and FRAXE: the results of a five-year survey. J. Med. Genet. 37, 415\u2013421 (2000).<\/p>\n CAS<\/a>\u00a0 Schulz, J. B. et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat. Rev. Neurol. 5, 222\u2013234 (2009).<\/p>\n PubMed<\/a>\u00a0 Mosbach, V. & Puccio, H. A multiple animal and cellular models approach to study frataxin deficiency in Friedreich ataxia. Biochim. Biophys. Acta Mol. Cell Res. 1871, 119809 (2024).<\/p>\n CAS<\/a>\u00a0 Schreiber, A. M., Li, Y., Chen, Y. H., Napierala, J. S. & Napierala, M. Selected histone deacetylase inhibitors reverse the Frataxin transcriptional defect in a novel Friedreich\u2019s ataxia induced pluripotent stem cell-derived neuronal reporter system. Front. Neurosci. 16, 836476 (2022).<\/p>\n PubMed<\/a>\u00a0 Lyst, M. J. & Bird, A. Rett syndrome: a complex disorder with simple roots. Nat. Rev. Genet. 16, 261\u2013274 (2015).<\/p>\n CAS<\/a>\u00a0 Gold, W. A. et al. Rett syndrome. Nat. Rev. Dis. Primers 10, 84 (2024).<\/p>\n PubMed<\/a>\u00a0 Qian, J. et al. Multiplex epigenome editing of MECP2 to rescue Rett syndrome neurons. Sci. Transl. Med. 15, eadd4666 (2023).<\/p>\n CAS<\/a>\u00a0 Pescatore, A., Esposito, E., Draber, P., Walczak, H. & Ursini, M. V. NEMO regulates a cell death switch in TNF signaling by inhibiting recruitment of RIPK3 to the cell death-inducing complex II. Cell Death Dis. 7, e2346 (2016).<\/p>\n CAS<\/a>\u00a0 Parrish, J. E., Scheuerle, A. E., Lewis, R. A., Levy, M. L. & Nelson, D. L. Selection against mutant alleles in blood leukocytes is a consistent feature in incontinentia pigmenti type 2. Hum. Mol. Genet. 5, 1777\u20131783 (1996).<\/p>\n CAS<\/a>\u00a0 Kenwrick, S. et al. Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome. Am. J. Hum. Genet. 69, 1210\u20131217 (2001).<\/p>\n CAS<\/a>\u00a0 Fusco, F., Fimiani, G., Tadini, G., Michele, D. & Ursini, M. V. Clinical diagnosis of incontinentia pigmenti in a cohort of male patients. J. Am. Acad. Dermatol. 56, 264\u2013267 (2007).<\/p>\n PubMed<\/a>\u00a0 Reik, W. & Walter, J. Genomic imprinting: parental influence on the genome. Nat. Rev. Genet. 2, 21\u201332 (2001).<\/p>\n CAS<\/a>\u00a0 Buiting, K., Williams, C. & Horsthemke, B. Angelman syndrome \u2014 insights into a rare neurogenetic disorder. Nat. Rev. Neurol. 12, 584\u2013593 (2016).<\/p>\n CAS<\/a>\u00a0 Wakeling, E. L. Silver\u2013Russell syndrome. Arch. Dis. Child. 96, 1156\u20131161 (2011).<\/p>\n PubMed<\/a>\u00a0 Cassidy, S. B., Schwartz, S., Miller, J. L. & Driscoll, D. J. Prader\u2013Willi syndrome. Genet. Med. 14, 10\u201326 (2012).<\/p>\n CAS<\/a>\u00a0 Docherty, L. E. et al. Clinical presentation of 6q24 transient neonatal diabetes mellitus (6q24 TNDM) and genotype\u2013phenotype correlation in an international cohort of patients. Diabetologia 56, 758\u2013762 (2013).<\/p>\n CAS<\/a>\u00a0 Choufani, S., Shuman, C. & Weksberg, R. Beckwith\u2013Wiedemann syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 154C, 343\u2013354 (2010).<\/p>\n CAS<\/a>\u00a0 Huang, H. S. et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 481, 185\u2013191 (2011).<\/p>\n PubMed<\/a>\u00a0 Vihma, H. et al. Ube3a unsilencer for the potential treatment of Angelman syndrome. Nat. Commun. 15, 5558 (2024).<\/p>\n CAS<\/a>\u00a0 Wolter, J. M. et al. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA. Nature 587, 281\u2013284 (2020).<\/p>\n CAS<\/a>\u00a0 Schmid, R. S. et al. CRISPR\/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. J. Clin. Invest. 131, e142574 (2021).<\/p>\n CAS<\/a>\u00a0 Rohm, D. et al. Activation of the imprinted Prader\u2013Willi syndrome locus by CRISPR-based epigenome editing. Cell Genom. 5, 100770 (2025).<\/p>\n CAS<\/a>\u00a0 Wang, S. E. & Jiang, Y.-H. Novel epigenetic molecular therapies for imprinting disorders. Mol. Psychiatry 28, 3182\u20133193 (2023).<\/p>\n PubMed<\/a>\u00a0 Garber, K. B., Visootsak, J. & Warren, S. T. Fragile X syndrome. Eur. J. Hum. Genet. 16, 666\u2013672 (2008).<\/p>\n CAS<\/a>\u00a0 Rodriguez-Revenga, L. et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur. J. Hum. Genet. 17, 1359\u20131362 (2009).<\/p>\n CAS<\/a>\u00a0 Tassone, F. et al. Elevated levels of FMR1 mRNA carrier males: a new mechanism of involvement in the fragile-X syndrome. Am. J. Hum. Genet. 66, 6\u201315 (2000).<\/p>\n CAS<\/a>\u00a0 Tassone, F. et al. Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA 13, 555\u2013562 (2007).<\/p>\n CAS<\/a>\u00a0 Kraan, C. M., Godler, D. E. & Amor, D. J. Epigenetics of fragile X syndrome and fragile X-related disorders. Dev. Med. Child Neurol. 61, 121\u2013127 (2019).<\/p>\n PubMed<\/a>\u00a0 Landy, S. J. & Donnai, D. Incontinentia pigmenti (Bloch\u2013Sulzberger syndrome). J. Med. Genet. 30, 53\u201359 (1993).<\/p>\n CAS<\/a>\u00a0 Vaghani, U. P. et al. Bloch\u2013Sulzberger syndrome: a rare X-linked dominant genetic disorder in a newborn. Cureus 15, e48823 (2023).<\/p>\n PubMed<\/a>\u00a0 Prasasya, R., Grotheer, K. V., Siracusa, L. D. & Bartolomei, M. S. Temple syndrome and Kagami\u2013Ogata syndrome: clinical presentations, genotypes, models and mechanisms. Hum. Mol. Genet. 29, R107\u2013R116 (2020).<\/p>\n PubMed<\/a>\u00a0 Baena, N. et al. Novel 14q32.2 paternal deletion encompassing the whole DLK1 gene associated with Temple syndrome. Clin. Epigenetics 16, 62 (2024).<\/p>\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n","protected":false},"excerpt":{"rendered":"Ng, S. B. et al. Exome sequencing identifies the cause of a Mendelian disorder. Nat. Genet. 42, 30\u201335…\n","protected":false},"author":2,"featured_media":16153,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[2342,13114,258,8869,13113,257,200,3870,15297,79,15298],"class_list":["post-16152","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-agriculture","tag-animal-genetics-and-genomics","tag-biomedicine","tag-cancer-research","tag-gene-function","tag-general","tag-genetics","tag-human-genetics","tag-neurodevelopmental-disorders","tag-science","tag-stem-cells"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/16152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=16152"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/16152\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/16153"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=16152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=16152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=16152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}